Rizatriptan Benzoate Tablets Recalled for Excessive N-Nitroso Impurity
Glenmark Pharmaceuticals recalls certain Rizatriptan Benzoate tablets due to N-Nitroso Desmethyl Rizatriptan impurity levels exceeding FDA acceptable limits. The affected lots were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for impurity contamination above FDA acceptable limits. Per the severity rubric, FDA Class II recalls for manufacturing deviations represent a risk-of-harm product, warranting a High severity classification.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling certain lots of Rizatriptan Benzoate Tablets USP, 10 mg due to current good manufacturing practice (CGMP) deviations. Testing identified N-Nitroso Desmethyl Rizatriptan impurity levels that exceed FDA acceptable limits.
The affected lots—19224217 (expiration 9/2024), 19233789 (expiration 9/2025), and 19224444 (expiration 9/2024)—total approximately 11,976 cartons distributed nationwide throughout the United States.
Patients currently using affected lots should contact their healthcare provider or pharmacist for guidance. Do not dispose of medication in household waste; consult a pharmacy or poison control center for proper disposal instructions.
The recalled product
- Product
- RIZATRIPTAN BENZOATE (RIZATRIPTAN BENZOATE)
- Brand
- RIZATRIPTAN BENZOATE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Affected units
- 11,976
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot#: 19224217
- Exp. 9/2024 Lot#: 19233789
- Exp. 9/2025 Lot#: 19224444
- Exp. 9/2024
UPCs (2)
- 0368462465998
- 0368462466995
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · RIZATRIPTAN BENZOATE
- HighRizatriptan 5 mg tablets exceed the acceptable intake limit for nitrosamine
FDA (Drugs) · 2025-07-23
- HighRizatriptan 10 mg tablets exceed the acceptable intake limit for nitrosamine
FDA (Drugs) · 2025-07-23
- HighFDA Recalls Rizatriptan Benzoate Tablets for Manufacturing Impurity
FDA (Drugs) · 2024-06-12
- HighPrescription Rizatriptan Benzoate Tablets Recalled for Chemical Impurity
FDA (Drugs) · 2024-06-12
- HighPrescription migraine drug recalled for manufacturing impurity above FDA limit
FDA (Drugs) · 2024-06-12
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17